Congenital Heart Disease Associated Pulmonary Arterial Hypertension

Clinics in Chest Medicine

Volumn 28, Issue 1, 2007, Pages 243-253

  Landzberg, Michael J ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ILOPROST; PLACEBO; PROSTACYCLIN; SILDENAFIL; UNIPROST;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL HEART DISEASE; DIAGNOSTIC IMAGING; DISEASE COURSE; EISENMENGER COMPLEX; ERYTHROCYTOSIS; HEART ATRIUM SEPTUM DEFECT; HEART GRAFT; HEART LEFT RIGHT SHUNT; HEART SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; LUNG ARTERIOVENOUS SHUNT; LUNG BLOOD FLOW; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; LUNG VENTILATION PERFUSION RATIO; NUCLEAR MAGNETIC RESONANCE IMAGING; PATENT DUCTUS ARTERIOSUS; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SURGICAL TECHNIQUE;

CARDIAC SURGICAL PROCEDURES; EISENMENGER COMPLEX; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 33847391492     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2006.12.004     Document Type: Review

References (65)

1. Friedman W.F. Proceedings of National Heart, Lung and Blood Institute pediatric cardiology workshop: pulmonary hypertension. Pediatr Res 20 (1986) 811-824
2. Kidd L., Driscoll D.J., Gersony W.M., et al. Second natural history study of congenital heart defects: results of treatment of patients with ventricular septal defects. Circulation 87 (1993) 138-151
3. Diller G.P., Dimopoulis K., Okonko D., et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 112 (2005) 828-835
4. Simonneau G., Galie N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 Suppl (2004) 5S-12S
5. Galie N. Classification of patients with congenital systemic-to-pulmonary shunts associated with pulmonary arterial hypertension: current status and future directions. In: Beghetti M. (Ed). Pulmonary arterial hypertension related to congenital heart disease (2006), Elsevier GmbH, Munich (Germany) 11-17
6. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 46 (1958) 701-709
7. Rabinovitch M., Haworth S.G., Castaneda A.R., et al. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 58 (1978) 1107-1122
8. Fratz S., Geiger R., Kresse H., et al. Pulmonary blood pressure, not flow, is associated with net endotehlin-1 production in the lungs of patients with congenital heart disease and normal pulmonary vascular resistance. J Thorac Cardiovasc Surg 126 (2003) 1724-1729
9. van Albada M.E., Shoemaker R.G., Kemna M.S., et al. The role of increased pulmonary blood flow in pulmonary arterial hypertension. Eur Respir J 26 (2005) 487-493
10. Black S.M., Bekker J.M., Johengen M.J., et al. Altered regulation of the ET-1 cascade in lambs with increased pulmonary blood flow and pulmonary hypertension. Pediatr Res 47 (2000) 97-106
11. Van Beneden R., Rondelet B., Kerbaul F., et al. Ang-1/BMPR2 signalling and the expression of MCP-1 and ICAM in overcirculation-induced experimental pulmonary hypertension. Eur Respir J 24 (2004) 533S
12. Mata-Greenwood E., Meyrick B., Soifer S.J., et al. Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 285 (2003) L222-L231
13. Cornfield D.N., Resnik E.R., Herron J.M., et al. Pulmonary vascular K+ channel expression and vasoreactivity in a model of congenital heart disease. Am J Physiol Lung Cell Mol Physiol 283 (2002) L1210-L1219
14. Black S.M., Sanchez L.S., Mata-Greenwood E., et al. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 281 (2001) L1051-L1057
15. Fratz S., Meyrick B., Ovadia B., et al. Chronic endothelin A receptor blockade in lambs with increased pulmonary blood flow and pressure. Am J Physiol Lung Cell Mol Physiol 287 (2004) L592-L597
16. Rondelet B., Kerbaul F., Motte S., et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 107 (2003) 1329-1335
17. Rondelet B., Kerbaul F., Van Beneden R., et al. Signalling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. Circulation 110 (2004) 2220-2225
18. Galie N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
19. Bolger A.P., Sharma R., Li W., et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106 (2002) 92-99
20. Cacoub P., Dorent R., Maistre G., et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol 71 (1993) 448-450
21. Ishikawa S., Miyauchi T., Sakai S., et al. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J Thorac Cardiovasc Surg 110 (1995) 271-273
22. Cacoub P., Dorent R., Nataf P., et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 33 (1997) 196-200
23. Roberts K.E., McElroy J.J., Wong W.P., et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 24 (2004) 371-374
24. Steele P.M., Fuster V., Cohen M., et al. Isolated atrial septal defect with pulmonary vascular obstructive disease: long-term follow-up and prediction of outcome after surgical correction. Circulation 76 (1987) 1037-1042
25. Batista R.J., Santos J.L., Takeshita N., et al. Successful reversal of pulmonary hypertension in Eisenmenger complex. Arq Bras Cardiol 68 4 (1997) 279-280
26. Daliento L., Somerville J., Presbitero P., et al. Eisenmenger syndrome: factors relating to deterioration and death. Eur Heart J 19 (1998) 1845-1855
27. Saha A., Balakrishnan K., Jaiswal P., et al. Prognosis for patients with Eisenmenger syndrome of various aetiology. Int J Cardiol 45 (1994) 199-207
28. Vongpatanasin W., Brickner M.E., Hillis L.D., et al. The Eisenmenger syndrome in adults. Ann Intern Med 128 (1998) 745-755
29. Cantor W.J., Harrison D.A., Moussadji J.S., et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol 84 (1999) 677-681
30. Kilner P. Cardiovascular magnetic resonance imaging. In: Gatzoulis M.A., Webb G.D., and Daubeney P.E.F. (Eds). Diagnosis and management of adult congenital heart disease (2003), Elsevier Limited, London 49-56
31. Sondel P.M., Tripp M.E., Ganick D.J., et al. Phlebotomy with iron therapy to correct the microcytic polycythemia of chronic hypoxia. Pediatrics 67 (1981) 667-670
32. Perloff J.K., Marelli A.J., and Miner P.D. Risk of stroke in adults with cyanotic congenital heart disease. Circulation 87 (1993) 1954-1959
33. Jones P., and Patel A. Eisenmenger's syndrome and problems with anaesthesia. Br J Hosp Med 54 5 (1996) 214-219
34. Bowyer J.J., Busst C.M., Denison D.M., et al. Effect of long-term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 55 (1986) 385-390
35. Sandoval J., Aguirre J.S., Pulido T., et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 164 (2001) 1682-1687
36. Gildein H.P., Wildberg A., and Moellin R. Comparative studies of hemodynamics under prostacyclin and nifedipine in patients with Eisenmenger syndrome. Z Kardiol (Germany) 84 (1995) 55-63
37. Trulock E.P. Lung transplantation for primary pulmonary hypertension. Clin Chest Med 22 (2001) 583-593
38. Silversides C.K., Granton J.T., Konen T., et al. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 42 (2003) 1982-1987
39. Rosove M.H., Hocking W.G., Harwig S.S., et al. Studies of beta-thromboglobulin, platelet factor 4, fibrinopeptide-A in erythrocytosis due to cyanotic congenital heart disease. Thromb Res 29 (1983) 225-235
40. Rosenzweig E.B., Kerstein D., and Barst R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99 (1999) 1858-1865
41. McLaughlin V.V., Genthner D.E., Panella M.M., et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 130 (1999) 740-743
42. Ferndandes S.M., Newburger J.W., Lang P., et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 91 (2003) 46-49
43. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
44. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 (1996) 296-302
45. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
46. Galie N., Humbert M., Vachiery J.L., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39 (2002) 1496-1502
47. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
48. Barst R.J., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
49. Bando K., Turrentine M.W., Sharp T.G., et al. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg 112 (1996) 1600-1607
50. Wessel D., Adatia I., Giglia T.M., et al. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial dysfunction after cardiopulmonary bypass. Circulation 88 (1993) 2128-2138
51. Adatia I., Barrow S., Stratton P., et al. Effect of intracardiac repair on biosynthesis of thromboxane A2 and prostacyclin in children with a left to right shunt. Br Heart J 72 (1994) 452-456
52. Schulze-Nieck I., Penny D.J., Rigby M.L., et al. L-arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery. Circulation 100 (1999) 749-755
53. Hiramatsu T., Imai Y., Takanishsi Y., et al. Time course of endothelin-1 and nitrate anion levels after cardiopulmonary bypass in congenital heart defects. Ann Thorac Surg 63 (1997) 648-652
54. Carroll C.L., Backer C.L., Mavroudis C., et al. Inhaled prostacyclin following surgical repair of congenital heart disease: a pilot study. J Card Surg 20 (2005) 436-439
55. Ivy D.D., Kinsella J.P., Ziegler J.W., et al. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 115 (1998) 875-882
56. Atz A.M., Lefler A.K., Fairbrother D.L., et al. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 124 (2002) 628-629
57. Schulze-Neick I., Li J., Reader J.A., et al. The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease. J Thorac Cardiovasc Surg 124 (2002) 435-441
58. Miller O.I., Tang S.F., Keech A., et al. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 356 (2000) 1464-1469
59. Smith H.A., Canter J.A., Christian K.G., et al. Nitric oxide precursors and congenital heart surgery: a randomized controlled trial of oral citrulline. J Thorac Cardiovasc Surg 132 (2006) 58-65
60. Schulze-Neick I., Li J., Penny D.J., et al. Pulmonary vascular resistance after cardiopulmonary bypass in infants: effect on postoperative recovery. J Thorac Cardiovasc Surg 121 (2001) 1033-1039
61. Bradley S.M., Simsic J.M., and Mulvihill D.M. Hypoventilation improves oxygenation after bidirectional superior cavopulmonary connection. J Thorac Cardiovasc Surg 126 (2003) 1033-1039
62. Hoskote A., Li J., Hickey C., et al. The effects of carbon dioxide on oxygenation and systemic, cerebral and pulmonary vascular hemodynamics after the bidirectional superior cavopulmonary anastomosis. J Am Coll Cardiol 44 (2004) 1501-1509
63. Guadagni G., Bove E.L., Migliavacca F., et al. Effects of pulmonary afterload on the hemodynamics after the hemi-Fontan procedure. Med Eng Phys 23 (2001) 293-298
64. Ikai A., Shirai M., Nishimura K., et al. Hypoxic pulmonary vasoconstriction disappears in a rabbit model of cavopulmonary shunt. J Thorac Cardiovasc Surg 127 (2004) 1450-1457
65. Simsic J.M., Bradley S.M., and Mulvihill D.M. Sodium nitroprusside after bidirectional superior cavopulmonary connection: preserved cerebral blood flow velocity and systemic oxygenation. J Thorac Cardiovasc Surg 126 (2003) 186-190